BUZZ-Jefferies looks to Lilly data to reignite interest in obesity stocks

Reuters03-05

** Brokerage Jefferies says investor sentiment on obesity stocks is "mixed" at best, but hopes that positive data from Eli Lilly's LLY.N oral obesity drug will bring investors back into this space

** LLY shares fell 8% after company's Q3 weight-loss drug sales missed estimates, but have since recovered; its stock is up 19% YTD

** LLY is expected to report late-stage data on its experimental obesity drug, orforglipron, by April

** "We would like to see positive LLY orfo data help drive the obesity comps back up and bring investors back into this space" - Jefferies

** Outside LLY as the leader, Jefferies says it likes Amgen AMGN.O and Structure Therapeutics GPCR.O, which are both expected to report data on their experimental drugs in H2

** AMGN up 11.7%, GPCR down 46.6% and LLY up 14.9% in the past 12 months

(Reporting by Christy Santhosh and Siddhi Mahatole)

((Christy.Santhosh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment